Trial | NCT04613271  Report issue

Title

Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    130
The benefit of the research is to provide information regarding the efficacy and safety of Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a reference for policy recommendations regarding the use of Favipiravir as an antiviral drug for the treatment of Covid-19.
Pre-screening is assessing patients who meet the inclusion and exclusion criteria. Screening was carried out to assess whether the subjects met the inclusion and exclusion criteria. Randomization was performed to determine the study drug allocation. The research subjects were inpatients at selected hospitals and at the time of recruitment, the time was called D1. The next day is called D2 and so on Follow-up will be carried out from the first day of recruitment, taking medication up to a maximum of 19 days for test drugs and 11 days for SoC drugs. Recording of clinical and laboratory manifestations will be carried out from recruitment until the patient returns from the hospital.

All results will be recorded in a case report form, and if a case of clinical and laboratory manifestations is found to be severe, it will be written on the adverse case report form and reported immediately according to standard GCP procedures. Subjects may also drop out of the study due to discontinuation of follow-up or a protocol violation
Study Started
Oct 15
2020
Primary Completion
Oct 25
2021
Study Completion
Nov 08
2021
Last Update
Mar 08
2023

Drug Favipiravir

Assignment of Administration Group 1: Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.

  • Other names: Treatment Group

Drug Azithromycin

Azithromycin 500 mg once a day for 5 days.

  • Other names: Group 2

Group 1 Experimental

Assignment of Administration Group 1: Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.

Group 2 Active Comparator

Administration Group 2: Azithromycin 500 mg once a day for 5 days.

Criteria 

Inclusion Criteria:

Adult patients 18 years - 59 years
Confirmation of Covid-19 based on the results of the Real Time PCR (RTPCR) examination for SARS-COV-2 less than 7 days before the first day of taking the drug
Patients with mild-moderate clinical manifestations were admitted to the hospital designated by the physician according to the operational definition of the study protocol
Have not received COVID-19 antiviral therapy
Consciously and voluntarily participate in research

Exclusion Criteria:

Pregnant and lactating women
Allergy history to Favipiravir and standard hospital drugs
Patients with uric acid examination values above normal male> 7 mg / dL; women> 5.7 mg / dL
Patients with a history of prolonged ECG / Arrhythmia / QT disorders
Cannot swallow drug
No Results Posted